3654 results for «365»

Filter By

3654 results

Coronary interventions: first-in-man and novel devices

20 May 2026 – From EuroPCR 2026

Explore pioneering advancements in coronary interventions with first-in-man and novel devices. This session presents groundbreaking studies including cryotherapy for vulnerable plaques, a novel intravascular crossing system for coronary CTOs, sirolimus-coated retrievable scaffold therapy for in-stent restenosis, real-time intravascular photoacoustic imaging of lipid-rich plaques, and the inaugural...

Bifurcation PCI with complications - Part 2

20 May 2026 – From EuroPCR 2026

This session addresses the challenges and complications encountered during bifurcation PCI. Topics include managing the hairpin hazard, advanced techniques for coronary guidewire entrapment, dual device failure in complex interventions, strategies for trifurcation lesions, and the implications of tissue entrapment in malapposed stents within the left main...

When the anterior leaflet gets in the way: mitral leaflet modification before TMVR

19 May 2026 – From EuroPCR 2026

This session addresses the intricacies of mitral leaflet modification techniques prior to transcatheter mitral valve replacement (TMVR). It features innovative approaches such as LAMPOON-assisted valve-in-ring replacement, balloon-assisted leaflet translocation, and strategies to overcome the challenges posed by mitral annular calcification.

PCR's Got Talent Round 1 - Session 2

19 May 2026 – From EuroPCR 2026

PCR's Got Talent Round 1 - Session 2 offers a diverse collection of studies addressing coronary microvascular dysfunction, atrial fibrillation management, TAVI outcomes, AI applications in imaging, mitral and tricuspid valve interventions, and in-stent restenosis treatment. The session culminates with deliberations and results announcements, reflecting cutting-edge...

How to face resistent hypertension: when pharmacological treatment is not an option

19 May 2026 – From EuroPCR 2026

Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.

FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case

19 May 2026 – From EuroPCR 2026

A 71‑year‑old man with hypertension and dyslipidemia presented with CCS class II angina and three‑vessel coronary artery disease. Functional assessment included CT‑derived micro‑FFR, angiography‑based FFR, and stress myocardial scintigraphy. The only hemodynamically significant lesion was a long, calcified lesion of the LAD.

Lesion preparation was performed with...

FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case

TAVI procedural complications - Part 3: vascular complications, coronary issues and more

19 May 2026 – From EuroPCR 2026

This session addresses critical procedural complications during TAVI, emphasizing vascular issues, coronary complications, and complex bailout scenarios. Through challenging case examples, it offers insights into the management and anticipation of such complications to optimize patient outcomes.

Identifying problems and solving complex anatomies during TAVI

19 May 2026 – From EuroPCR 2026

A comprehensive session on managing complex anatomies during Transcatheter Aortic Valve Implantation (TAVI), emphasizing risk markers for peri-operative complications and strategies to address difficult anatomical challenges. Real-world cases illustrate practical approaches and key learnings for handling intricate TAVI scenarios.

Transcatheter management of failed THV - LIVE case

09 Feb 2025 – From PCR Tokyo Valves 2025

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

Transcatheter management of failed THV - LIVE case

Highlights of science and education in cardiovascular interventional medicine in 2025

22 Dec 2025

Dear Colleagues, dear PCR Companions,

As we welcome a New Year, it is the perfect time to reflect on what we achieved together over the past year - both as a celebration of our collective success and as motivation to continue improving in the year ahead.

2025 was...

PCRonline: Best of science & education in 2025

World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!

29 Sep 2023

Global burden of Cardiovascular Disease

Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...

Vijay Kunadian

Author

Vijay Kunadian
World Heart Day 2023

The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030

29 Aug 2021

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Vijay Kunadian

Author

Vijay Kunadian
ESC Congress 2021 - Global burden of cardiovascular disease in women; 20/20 vision for 2030: report of The Lancet commission

BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

07 Nov 2022

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Nicola Ryan

Author

Nicola Ryan
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

04 Nov 2024

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali

Alessandro Sticchi

Author

Alessandro Sticchi
TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation
Didn’t find what you were looking for?